1-4 of 4
Kamel Malek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Amer M. Zeidan, Pierre Fenaux, Xia Han, David A. James, Kamel Malek, Pedro Marques Ramos, Yasushi Miyazaki, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3236.
https://doi.org/10.1182/blood-2023-180765
Published: 2023
Journal Articles

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker
Journal: Blood
Blood (2022) 140 (Supplement 1): 2063–2065.
https://doi.org/10.1182/blood-2022-158612
Published: 2022
Journal Articles

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Jordi Esteve, Aristoteles Giagounidis, Hee-Je Kim, MD, PhD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Andre C. Schuh, Mikkael A. Sekeres, Jörg Westermann, Zhijian Xiao, Kamel Malek, Jeffrey Scott, Julie Niolat, Severine Peyrard, Fei Ma, Flavia Kiertsman, Mario Stegert, Sabine Hertle, Pierre Fenaux, MD PhD, Valeria Santini
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134718
Published: 2020
Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Amer M Zeidan, MD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Kamel Malek, Julie Niolat, Flavia Kiertsman, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4259.
https://doi.org/10.1182/blood-2019-127041
Published: 2019